daratumumab (Darzalex®)

Status: Excluded due to NICE appraisal

Product meets AWMSG exclusion criteria due to NICE appraisal: TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable

Medicine details

Medicine name

daratumumab (Darzalex®)

Formulation

20 mg/ml solution for infusion

Reference number

4237

Indication

For use in combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant

Company

Janssen-Cilag Ltd

BNF chapter

Malignant disease & immunosuppression

Assessment type

N/A

Status

Excluded due to NICE appraisal

Date of issue

22/09/2023

NICE guidance

TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable